Viewing Study NCT06038461


Ignite Creation Date: 2025-12-24 @ 11:45 AM
Ignite Modification Date: 2026-01-07 @ 12:33 AM
Study NCT ID: NCT06038461
Status: RECRUITING
Last Update Posted: 2024-10-01
First Post: 2023-09-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neuroendocrine Tumors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Surufatinib View
None Temozolomide and S-1 View
None First-line treatment View